Progyny, Inc. Announces Fourth Quarter and Full Year 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Progyny (PGNY) Misses Q4 EPS by 1c, Revenues Miss; Offers Q1 & FY20 EPS/Revenue Outlook
March 5, 2020 4:16 PM ESTProgyny (NASDAQ: PGNY) reported Q4 EPS of $0.01, $0.01 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $65.12 million versus the consensus estimate of $66.07 million.
We had a strong fourth quarter, concluding a record year for Progyny, said David Schlanger, Chief Executive Officer of Progyny. In 2019, our selling season produced the greatest number of new clients and covered lives in our history, demonstrating that awareness of infertility as a medical condition is growing, and that employers are looking for leading benefits solutions that both provide the appropriate coverage and generate the best clinical... More
